CA2605442A1 - Compositions et methodes destinees a diagnostiquer et surveiller une maladie auto-immune et a predire une reponse therapeutique correspondante - Google Patents

Compositions et methodes destinees a diagnostiquer et surveiller une maladie auto-immune et a predire une reponse therapeutique correspondante Download PDF

Info

Publication number: CA2605442A1
Authority: CA; Canada
Prior art keywords: glycoprotein; autoimmune; iesca; gene; sequence
Prior art date: 2005-04-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002605442A

Other languages

English (en)

Inventor

Thomas E. Carey

Thankam S. Nair

Jennifer Gray-Beckman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Michigan Medical School

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-18

Filing date

2006-04-18

Publication date

2006-10-26

2006-04-18 Application filed by Individual filed Critical Individual

2006-10-26 Publication of CA2605442A1 publication Critical patent/CA2605442A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 133
208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 70
238000012544 monitoring process Methods 0.000 title claims abstract description 11
239000000203 mixture Substances 0.000 title description 33
230000004797 therapeutic response Effects 0.000 title description 2
238000011282 treatment Methods 0.000 claims abstract description 75
108090000288 Glycoproteins Proteins 0.000 claims abstract description 62
102000003886 Glycoproteins Human genes 0.000 claims abstract description 62
210000003027 ear inner Anatomy 0.000 claims abstract description 52
230000001363 autoimmune Effects 0.000 claims abstract description 46
230000004044 response Effects 0.000 claims abstract description 35
210000002985 organ of corti Anatomy 0.000 claims abstract description 32
230000001225 therapeutic effect Effects 0.000 claims abstract description 28
238000002560 therapeutic procedure Methods 0.000 claims abstract description 26
230000027455 binding Effects 0.000 claims description 62
210000002966 serum Anatomy 0.000 claims description 40
102100035954 Choline transporter-like protein 2 Human genes 0.000 claims description 37
101000948115 Homo sapiens Choline transporter-like protein 2 Proteins 0.000 claims description 34
238000010166 immunofluorescence Methods 0.000 claims description 34
238000001262 western blot Methods 0.000 claims description 34
206010011891 Deafness neurosensory Diseases 0.000 claims description 28
208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 28
231100000879 sensorineural hearing loss Toxicity 0.000 claims description 28
208000023573 sensorineural hearing loss disease Diseases 0.000 claims description 28
230000000694 effects Effects 0.000 claims description 22
238000002650 immunosuppressive therapy Methods 0.000 claims description 20
208000018359 Systemic autoimmune disease Diseases 0.000 claims description 14
238000001514 detection method Methods 0.000 claims description 14
206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 13
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 12
208000012322 Raynaud phenomenon Diseases 0.000 claims description 9
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 8
208000003782 Raynaud disease Diseases 0.000 claims description 8
208000010007 Cogan syndrome Diseases 0.000 claims description 7
201000006417 multiple sclerosis Diseases 0.000 claims description 6
208000011231 Crohn disease Diseases 0.000 claims description 5
230000003247 decreasing effect Effects 0.000 claims description 5
206010028417 myasthenia gravis Diseases 0.000 claims description 5
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
208000003807 Graves Disease Diseases 0.000 claims description 4
208000015023 Graves' disease Diseases 0.000 claims description 4
208000001204 Hashimoto Disease Diseases 0.000 claims description 4
241000721454 Pemphigus Species 0.000 claims description 4
208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
208000006424 autoimmune oophoritis Diseases 0.000 claims description 4
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
201000004988 autoimmune vasculitis Diseases 0.000 claims description 4
230000002349 favourable effect Effects 0.000 claims description 4
208000004124 rheumatic heart disease Diseases 0.000 claims description 4
201000000306 sarcoidosis Diseases 0.000 claims description 4
201000011580 granulomatous orchitis Diseases 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 description 233
101000948121 Cavia porcellus Choline transporter-like protein 2 Proteins 0.000 description 164
210000004027 cell Anatomy 0.000 description 135
150000007523 nucleic acids Chemical group 0.000 description 99
102000004169 proteins and genes Human genes 0.000 description 85
235000018102 proteins Nutrition 0.000 description 79
230000000750 progressive effect Effects 0.000 description 67
108090000765 processed proteins & peptides Proteins 0.000 description 66
102000039446 nucleic acids Human genes 0.000 description 65
108020004707 nucleic acids Proteins 0.000 description 65
102000004196 processed proteins & peptides Human genes 0.000 description 59
108020004414 DNA Proteins 0.000 description 56
229920001184 polypeptide Polymers 0.000 description 54
239000002773 nucleotide Substances 0.000 description 50
230000014509 gene expression Effects 0.000 description 49
125000003729 nucleotide group Chemical group 0.000 description 49
239000013598 vector Substances 0.000 description 47
108091028043 Nucleic acid sequence Proteins 0.000 description 41
239000000523 sample Substances 0.000 description 35
239000012634 fragment Substances 0.000 description 34
239000000427 antigen Substances 0.000 description 33
210000001519 tissue Anatomy 0.000 description 33
230000006872 improvement Effects 0.000 description 32
108091007433 antigens Proteins 0.000 description 31
102000036639 antigens Human genes 0.000 description 31
230000002146 bilateral effect Effects 0.000 description 31
108091033319 polynucleotide Proteins 0.000 description 31
102000040430 polynucleotide Human genes 0.000 description 31
239000002157 polynucleotide Substances 0.000 description 31
150000003431 steroids Chemical class 0.000 description 30
206010011878 Deafness Diseases 0.000 description 29
230000010370 hearing loss Effects 0.000 description 28
231100000888 hearing loss Toxicity 0.000 description 28
208000016354 hearing loss disease Diseases 0.000 description 28
108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
108091026890 Coding region Proteins 0.000 description 26
235000001014 amino acid Nutrition 0.000 description 26
238000003556 assay Methods 0.000 description 26
239000000047 product Substances 0.000 description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
241000701161 unidentified adenovirus Species 0.000 description 23
229940024606 amino acid Drugs 0.000 description 22
150000001413 amino acids Chemical class 0.000 description 22
238000009396 hybridization Methods 0.000 description 22
201000010099 disease Diseases 0.000 description 21
108091034117 Oligonucleotide Proteins 0.000 description 20
230000000295 complement effect Effects 0.000 description 20
239000003623 enhancer Substances 0.000 description 20
108020004999 messenger RNA Proteins 0.000 description 20
230000035772 mutation Effects 0.000 description 20
125000003275 alpha amino acid group Chemical group 0.000 description 18
238000013518 transcription Methods 0.000 description 18
230000035897 transcription Effects 0.000 description 18
238000012360 testing method Methods 0.000 description 17
230000002950 deficient Effects 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
230000004927 fusion Effects 0.000 description 15
230000001976 improved effect Effects 0.000 description 15
230000010076 replication Effects 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
241001465754 Metazoa Species 0.000 description 14
241000700605 Viruses Species 0.000 description 14
230000008488 polyadenylation Effects 0.000 description 14
230000008093 supporting effect Effects 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 14
-1 organic solvents Chemical class 0.000 description 13
230000001105 regulatory effect Effects 0.000 description 13
238000010186 staining Methods 0.000 description 13
238000012217 deletion Methods 0.000 description 12
230000037430 deletion Effects 0.000 description 12
230000006870 function Effects 0.000 description 12
108020001507 fusion proteins Proteins 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
238000001890 transfection Methods 0.000 description 12
230000006378 damage Effects 0.000 description 11
239000013604 expression vector Substances 0.000 description 11
239000000126 substance Substances 0.000 description 11
239000013603 viral vector Substances 0.000 description 11
241000282414 Homo sapiens Species 0.000 description 10
108091092195 Intron Proteins 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
210000002768 hair cell Anatomy 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
238000000746 purification Methods 0.000 description 10
238000012216 screening Methods 0.000 description 10
241000894007 species Species 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000003321 amplification Effects 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000003550 marker Substances 0.000 description 9
239000012528 membrane Substances 0.000 description 9
238000003199 nucleic acid amplification method Methods 0.000 description 9
241000700199 Cavia porcellus Species 0.000 description 8
108091034057 RNA (poly(A)) Proteins 0.000 description 8
108700008625 Reporter Genes Proteins 0.000 description 8
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
239000002253 acid Substances 0.000 description 8
238000007792 addition Methods 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
229940000406 drug candidate Drugs 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
210000003128 head Anatomy 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
108700028369 Alleles Proteins 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 7
208000001065 Unilateral Hearing Loss Diseases 0.000 description 7
210000003527 eukaryotic cell Anatomy 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
230000008569 process Effects 0.000 description 7
230000001177 retroviral effect Effects 0.000 description 7
230000001953 sensory effect Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
238000012546 transfer Methods 0.000 description 7
108020005544 Antisense RNA Proteins 0.000 description 6
241000894006 Bacteria Species 0.000 description 6
208000000477 Bilateral Hearing Loss Diseases 0.000 description 6
101710148301 Choline transporter-like protein 2 Proteins 0.000 description 6
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 6
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 6
206010061373 Sudden Hearing Loss Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
210000003477 cochlea Anatomy 0.000 description 6
239000003184 complementary RNA Substances 0.000 description 6
210000005069 ears Anatomy 0.000 description 6
238000001415 gene therapy Methods 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
238000007899 nucleic acid hybridization Methods 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
238000012545 processing Methods 0.000 description 6
238000011160 research Methods 0.000 description 6
230000009261 transgenic effect Effects 0.000 description 6
241000702421 Dependoparvovirus Species 0.000 description 5
241000196324 Embryophyta Species 0.000 description 5
108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
239000000020 Nitrocellulose Substances 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
108091081021 Sense strand Proteins 0.000 description 5
241000700584 Simplexvirus Species 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000005784 autoimmunity Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
239000003446 ligand Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
229920001220 nitrocellulos Polymers 0.000 description 5
239000013641 positive control Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000013519 translation Methods 0.000 description 5
241000972773 Aulopiformes Species 0.000 description 4
101710163595 Chaperone protein DnaK Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 4
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
238000004422 calculation algorithm Methods 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
229940072221 immunoglobulins Drugs 0.000 description 4
239000002502 liposome Substances 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
235000019515 salmon Nutrition 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
238000005406 washing Methods 0.000 description 4
241000283707 Capra Species 0.000 description 3
108090000565 Capsid Proteins Proteins 0.000 description 3
108090000994 Catalytic RNA Proteins 0.000 description 3
102000053642 Catalytic RNA Human genes 0.000 description 3
102100023321 Ceruloplasmin Human genes 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
241000450599 DNA viruses Species 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000122159 Modiolus Species 0.000 description 3
241001529936 Murinae Species 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
108020004566 Transfer RNA Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000000356 contaminant Substances 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
229960002086 dextran Drugs 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
206010025135 lupus erythematosus Diseases 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000005012 migration Effects 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
210000001236 prokaryotic cell Anatomy 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
108091092562 ribozyme Proteins 0.000 description 3
238000007423 screening assay Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
241000271566 Aves Species 0.000 description 2
101150099461 CTL2 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
102100029727 Enteropeptidase Human genes 0.000 description 2
108010013369 Enteropeptidase Proteins 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
238000000729 Fisher's exact test Methods 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
102000002812 Heat-Shock Proteins Human genes 0.000 description 2
108010004889 Heat-Shock Proteins Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000000975 co-precipitation Methods 0.000 description 2
238000002742 combinatorial mutagenesis Methods 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000013399 early diagnosis Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
108700004025 env Genes Proteins 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
108700004026 gag Genes Proteins 0.000 description 2
229960002963 ganciclovir Drugs 0.000 description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
238000013537 high throughput screening Methods 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
238000005304 joining Methods 0.000 description 2
150000002611 lead compounds Chemical class 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
238000011068 loading method Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
229940064748 medrol Drugs 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
229940081221 methylprednisolone 24 mg Drugs 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000006152 selective media Substances 0.000 description 2
230000035939 shock Effects 0.000 description 2
210000001154 skull base Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
210000002205 spiral ligament of cochlea Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 2
229960001262 tramazoline Drugs 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
210000003454 tympanic membrane Anatomy 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000001720 vestibular Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
108020004465 16S ribosomal RNA Proteins 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
108020005065 3' Flanking Region Proteins 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
VHTUHGNVVZPWGO-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethyl-8-(pyridin-3-ylmethyl)purine-2,6-dione Chemical compound OCCN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1CC1=CC=CN=C1 VHTUHGNVVZPWGO-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701157 Canine mastadenovirus A Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
101150044789 Cap gene Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102100038909 Caveolin-2 Human genes 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
102000002494 Endoribonucleases Human genes 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
101000572820 Homo sapiens MICOS complex subunit MIC60 Proteins 0.000 description 1
101001132113 Homo sapiens Peroxisomal testis-specific protein 1 Proteins 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
208000027601 Inner ear disease Diseases 0.000 description 1
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
101150062031 L gene Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108020003217 Nuclear RNA Proteins 0.000 description 1
102000043141 Nuclear RNA Human genes 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102100034529 Peroxisomal testis-specific protein 1 Human genes 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
101100316117 Rattus norvegicus Unc50 gene Proteins 0.000 description 1
241001068295 Replication defective viruses Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
108020004688 Small Nuclear RNA Proteins 0.000 description 1
241000713896 Spleen necrosis virus Species 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
208000035286 Spontaneous Remission Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
208000009205 Tinnitus Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003491 array Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
238000012076 audiometry Methods 0.000 description 1
208000027625 autoimmune inner ear disease Diseases 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
108010086192 chymostatin Proteins 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000007878 drug screening assay Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000005447 environmental material Substances 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
231100000221 frame shift mutation induction Toxicity 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000046079 human IMMT Human genes 0.000 description 1
102000055066 human SLC44A2 Human genes 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
108010002685 hygromycin-B kinase Proteins 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000003960 inflammatory cascade Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000007170 pathology Effects 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000002823 phage display Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000032361 posttranscriptional gene silencing Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229940096335 prednisone 1 mg Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000030788 protein refolding Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
208000009305 pseudorabies Diseases 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
101150066583 rep gene Proteins 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000010255 response to auditory stimulus Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
108010010318 streptococcal M protein Proteins 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000002489 tectorial membrane Anatomy 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
231100000886 tinnitus Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
208000036000 unilateral deafness Diseases 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Rehabilitation Therapy (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA002605442A 2005-04-18 2006-04-18 Compositions et methodes destinees a diagnostiquer et surveiller une maladie auto-immune et a predire une reponse therapeutique correspondante Abandoned CA2605442A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67245305P	2005-04-18	2005-04-18
US60/672,453		2005-04-18
PCT/US2006/014575 WO2006113723A2 (fr)	2005-04-18	2006-04-18	Compositions et methodes destinees a diagnostiquer et surveiller une maladie auto-immune et a predire une reponse therapeutique correspondante

Publications (1)

Publication Number	Publication Date
CA2605442A1 true CA2605442A1 (fr)	2006-10-26

Family

ID=37115868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002605442A Abandoned CA2605442A1 (fr)	2005-04-18	2006-04-18	Compositions et methodes destinees a diagnostiquer et surveiller une maladie auto-immune et a predire une reponse therapeutique correspondante

Country Status (4)

Country	Link
EP (1)	EP1883420A4 (fr)
AU (1)	AU2006236406B2 (fr)
CA (1)	CA2605442A1 (fr)
WO (1)	WO2006113723A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8206564B2 (en)	2007-07-23	2012-06-26	Bayer Healthcare Llc	Biosensor calibration system
US7809512B2 (en)	2007-11-11	2010-10-05	Bayer Healthcare Llc	Biosensor coding system
EP2232251B1 (fr)	2007-12-10	2014-03-19	Bayer HealthCare LLC	Capteur d'essai à auto-calibrage et son procédé de fabrication
US8032321B2 (en)	2008-07-15	2011-10-04	Bayer Healthcare Llc	Multi-layered biosensor encoding systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030082646A1 (en) *	1998-12-29	2003-05-01	The Regents Of The University Of Michigan	Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
US20010006788A1 (en) *	1998-12-29	2001-07-05	Thomas E. Carey	Identifying the antigenic target of autoimmune sensorineural hearing loss (aisnhl) and developement of specific tests for diagnosis and management of aisnhl

2006
- 2006-04-18 CA CA002605442A patent/CA2605442A1/fr not_active Abandoned
- 2006-04-18 AU AU2006236406A patent/AU2006236406B2/en not_active Ceased
- 2006-04-18 WO PCT/US2006/014575 patent/WO2006113723A2/fr active Application Filing
- 2006-04-18 EP EP06750581A patent/EP1883420A4/fr not_active Withdrawn

Also Published As

Publication number	Publication date
WO2006113723A2 (fr)	2006-10-26
AU2006236406A1 (en)	2006-10-26
AU2006236406B2 (en)	2011-01-06
EP1883420A2 (fr)	2008-02-06
EP1883420A4 (fr)	2008-08-27
WO2006113723A3 (fr)	2007-06-14

Publication	Publication Date	Title
CA2427471C (fr)	2010-12-21	Acides nucleique et proteines nod2
US9758832B2 (en)	2017-09-12	Compositions for diagnosing episodic movement disorders and related conditions
US20090075268A1 (en)	2009-03-19	Antigenic Targets Of Autoimmune Sensorineural Hearing Loss (AISNHL) And Development Of Tests For Diagnosis And Management Of AISNHL
AU2006236406B2 (en)	2011-01-06	Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
US20050260623A1 (en)	2005-11-24	Oct-4 and GJIC expression as markers for adult human stem cells and cancer cell precursors
JP6608818B2 (ja)	2019-11-20	気分障害を診断、治療又は予防する方法
US7375086B2 (en)	2008-05-20	Modulators of Nod2 signaling
US7829292B2 (en)	2010-11-09	Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
CA2427684C (fr)	2012-03-06	Proteines et acides nucleiques nod2
AU2002227350A1 (en)	2002-07-18	Nod2 nucleic acids and proteins
WO2006052735A2 (fr)	2006-05-18	Fibuline-3 et ses utilisations
US20090098556A1 (en)	2009-04-16	Genetic Test For PSE-Susceptible Turkeys
AU2008201559B2 (en)	2010-07-22	Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
JP4848276B2 (ja)	2011-12-28	神経学的状態の検出および治療のための組成物および方法
US20040071700A1 (en)	2004-04-15	Obesity linked genes
WO2003100075A2 (fr)	2003-12-04	Acides nucleiques et proteines bsnd
WO2003091397A2 (fr)	2003-11-06	Techniques et compositions de regulation du signal cellulaire

Legal Events

Date	Code	Title	Description
2007-10-18	EEER	Examination request
2014-04-22	FZDE	Discontinued	Effective date: 20140225